In the KRAS mutation group, 120 cases (54.2%) developed tumor metastasis, and the frequent sites were lung metastasis (26 cases, 21.7%, P = 0.012) and brain metastasis (27 cases, 23.3%, P = 0.001). Here, KRAS is linked to neoplasm.